Alector Completes Enrollment for Phase 2 Alzheimer's Trial of AL101

MT Newswires Live04-18

Alector (ALEC) said Thursday it has completed enrollment for PROGRESS-AD, a 76-week phase 2 trial assessing the safety and effectiveness of AL101/GSK4527226 in slowing early-stage Alzheimer's disease progression.

Alector and GSK (GSK) are co-developing AL101, an investigational monoclonal antibody targeting the sortilin receptor to increase brain progranulin levels, currently being evaluated in PROGRESS-AD, a global, randomized, double-blind, placebo-controlled phase 2 trial led by GSK.

The trial is evaluating two dose levels of AL101, with participants randomized to receive either the drug or a placebo intravenously, and its primary endpoint is disease progression measured by the Clinical Dementia Rating Sum of Boxes, a validated tool for assessing cognitive decline, the biotechnology company said.

Shares of Alector were down 1.9% in recent Thursday trading, while GSK's were up 1%.

Price: 0.96, Change: -0.02, Percent Change: -1.87

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2528286057?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-18 00:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2528286057","market":"sh","top_or_hot":-1,"title":"Alector Completes Enrollment for Phase 2 Alzheimer's Trial of AL101","media":"MT Newswires Live","content":"<html><body><p> Alector (ALEC) said Thursday it has completed enrollment for PROGRESS-AD, a 76-week phase 2 trial assessing the safety and effectiveness of AL101/GSK4527226 in slowing early-stage Alzheimer's disease progression.</p><p>Alector and GSK (GSK) are co-developing AL101, an investigational monoclonal antibody targeting the sortilin receptor to increase brain progranulin levels, currently being evaluated in PROGRESS-AD, a global, randomized, double-blind, placebo-controlled phase 2 trial led by GSK.</p><p>The trial is evaluating two dose levels of AL101, with participants randomized to receive either the drug or a placebo intravenously, and its primary endpoint is disease progression measured by the Clinical Dementia Rating Sum of Boxes, a validated tool for assessing cognitive decline, the biotechnology company said.</p><p>Shares of Alector were down 1.9% in recent Thursday trading, while GSK's were up 1%.</p><p>Price: 0.96, Change: -0.02, Percent Change: -1.87</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alector Completes Enrollment for Phase 2 Alzheimer's Trial of AL101</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlector Completes Enrollment for Phase 2 Alzheimer's Trial of AL101\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-18 00:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Alector (ALEC) said Thursday it has completed enrollment for PROGRESS-AD, a 76-week phase 2 trial assessing the safety and effectiveness of AL101/GSK4527226 in slowing early-stage Alzheimer's disease progression.</p><p>Alector and GSK (GSK) are co-developing AL101, an investigational monoclonal antibody targeting the sortilin receptor to increase brain progranulin levels, currently being evaluated in PROGRESS-AD, a global, randomized, double-blind, placebo-controlled phase 2 trial led by GSK.</p><p>The trial is evaluating two dose levels of AL101, with participants randomized to receive either the drug or a placebo intravenously, and its primary endpoint is disease progression measured by the Clinical Dementia Rating Sum of Boxes, a validated tool for assessing cognitive decline, the biotechnology company said.</p><p>Shares of Alector were down 1.9% in recent Thursday trading, while GSK's were up 1%.</p><p>Price: 0.96, Change: -0.02, Percent Change: -1.87</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALEC","symbol_name":"Alector Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2528286057","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2528286057","pubTimestamp":1744905676,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Alector (ALEC) said Thursday it has completed enrollment for PROGRESS-AD, a 76-week phase 2 trial assessing the safety and effectiveness of AL101/GSK4527226 in slowing early-stage Alzheimer's disease ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALEC":"Alector Inc.","BK4585":"ETF&股票定投概念","BK4588":"碎股","GSK.UK":"葛兰素史克","GSK":"葛兰素史克","BK4139":"生物科技","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4532":"文艺复兴科技持仓","BK4007":"制药"},"translate_title":"Alector完成AL101 2期阿尔茨海默病试验的入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":0.9,"ALEC":0.9,"GSK.UK":0.6},"content_text":"Alector (ALEC) said Thursday it has completed enrollment for PROGRESS-AD, a 76-week phase 2 trial assessing the safety and effectiveness of AL101/GSK4527226 in slowing early-stage Alzheimer's disease progression.Alector and GSK (GSK) are co-developing AL101, an investigational monoclonal antibody targeting the sortilin receptor to increase brain progranulin levels, currently being evaluated in PROGRESS-AD, a global, randomized, double-blind, placebo-controlled phase 2 trial led by GSK.The trial is evaluating two dose levels of AL101, with participants randomized to receive either the drug or a placebo intravenously, and its primary endpoint is disease progression measured by the Clinical Dementia Rating Sum of Boxes, a validated tool for assessing cognitive decline, the biotechnology company said.Shares of Alector were down 1.9% in recent Thursday trading, while GSK's were up 1%.Price: 0.96, Change: -0.02, Percent Change: -1.87","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2528286057","isCrawlerRequest":true}